Surgery technique for subretinal haemorrhages combined with age-specific macular dystrophy with subretinal neovascular membrane
SUBSTANCE: invention refers to ophthalmology and can be used in surgery of subretinal haemorrhages combined with age-specific macular dystrophy with subretinal neovascular membrane. The technique involves subtotal vitrectomy and removal of posterior hyaloid membrane. Bevacizumab and Ranibizumab are injected intravitreally. It is followed with intravitreal injection of tissue plasminogen activator and expanding gas while a patient is pronated.
EFFECT: method allows deploying blood from under retina, ensuring pathogenetic action on haemorrhage source, preventing proliferative processes in vitreal cavity.
The invention relates to medicine, and more specifically to ophthalmology, and is intended for the surgical treatment of subretinal hemorrhage complicating the course of age-related macular degeneration with subretinal neovascular membrane (CNM).
Age-related macular degeneration ranks third after glaucoma and diabetic retinopathy among the causes of blindness in the second half of life. With increasing life expectancy of the population, the problem of age-related macular degeneration becomes very important. The loss of Central vision and total disability give this disease a large socio-medical significance. In 80-90% of cases of severe loss of Central vision associated with the formation of SNM in the Central zone of the retina. Quite often they are complicated by the appearance of submacular hemorrhage, optionally having toxic effects on sensitive neurosensory retina and significantly reduce the chances of recovery of vision.
Among the surgical techniques of dislocation of blood from beneath the Central area of the retina known: vitrectomy with intravitreal the introduction of tissue plasminogen activator, an isolated pneumatologia, YAG laser retinopathy, submacular surgery, the combined use of gas and tissue plasminogen activator Essence of these interventions is to more completely remove blood clots from the Central region to reduce the toxic effects of products of hemolysis in the photoreceptors and preventing the development of submacular proliferation.
A known method of surgical treatment of submacular hemorrhages by intravitreal injection of the expanding gas and tissue plasminogen activator without needing vitrectomy (Heriot W. Intravitreal gas and tPA: an outpatient procedure for submacular hemorrhage. Presented at: Meeting of the American Academy of Ophthalmology; Chicago: Octouber 1996; Chen C. Management of submacular hemorrhage with Intravitreal injection of tissue plasminogen activator and expansile gas. Retina 2007; 27: 321-328). He is slow intravitreal through the introduction of the flat part of the ciliary body of the diluted solution of a tissue plasminogen activator (TAP) at the dose of 100 mg/0.1 ml and 0.3-0.4 ml of gas perftoran (C3F8or sulfurhexafluoride (SF6). Within two days, the patient observes the position of the face. The contact of the blood clot from the TAP leads to its partial lysis and displacement under the action of gas from the macular area in the lower half of the retina.
The disadvantage of this method is the lack of impact on the etiological component subretinal hemorrhage: directly on subretinal neovascular membrane. Surgical intervention only leads to anatomical disposition of blood from the Central region, reducing its toxic effects on the retina, without affecting the visual prognosis, and functional results of operations, as a rule, limited by the presence in the macular area subretinal neous Blarney membrane. Introduction the expanding gas without prior vitrectomy leads to a change in the structure of the vitreous body, provokes the onset of the proliferative process, which can cause retinal detachment (according to different authors from 3 to 36% of cases).
The objective of the invention is to develop a method of surgical treatment of subretinal hemorrhage on the basis of age-related macular degeneration with the subretinal neovascularization with obtaining the highest functional outcomes and maximum reduction of postoperative complications.
The technical result achieved by using the proposed invention is the anatomical location of blood from the Central region of the retina, the pathogenetic impact on the source of the hemorrhage (subretinal neovascular membrane), preventing the development of proliferative processes in the vitreal cavity, reducing the risk of retinal detachment, which leads to better functional results of surgical intervention in the early and late postoperative periods.
The technical result is achieved in that in the method of surgical treatment of subretinal hemorrhage on the basis of age-related macular degeneration with SNM, including intravitreal injections of similar TAP - recombinant pourakino the s and the expanding gas perftoran (C 3F8or sulfurhexafluoride (SF6with the subsequent positioning of the patient face down, according to the invention before the intravitreal injection perform Subtotal vitrectomy with removal of the posterior hyaloid membrane and the introduction of intravitreal angiogenesis inhibitors (bevacizumab or ranibizumab).
The method allows to significantly increase the percentage of dislocation of blood from the macular region on the background of subretinal neovascularization, to reduce the number of postoperative complications, improve the functional prognosis of the disease, preventing re-bleeding and stabilizing process choroidal neovascularization.
As the active substance that promotes the lysis of subretinal blood clot can be used recombinant PUK ("Gamesa"LLC SPE "TECHNOGEN", patent No. 2216348). "Gamesa" is a lyophilized enzyme preparation containing recombinant PUK and catalyzes the conversion of plasminogen to plasmin is a serine protease that is able to lyse fibrin clots, and high specificity of action, as it activates plasminogen mainly in the area of the clot, which reduces the risk of possible bleeding and hemorrhage.
As action is found substances influencing the process choroidal neovascularization can be used angiogenesis inhibitor (bevacizumab or ranibizumab). This type of drugs are able to block all isoforms factor vascular endothelial growth (VEGF). Anti-VEGF therapy promotes partial regression of subretinal membranes, reducing their activity and stabilizes the process choroidal neovascularization.
As the active substance, affecting mechanical dislocation of blood from the Central region of the retina can be used expanding gas perftoran (C3F8or sulfurhexafluoride (SF6). Performing "massage" the macular area when positioned face down, he contributes to the gradual displacement of the hemorrhage in the lower half of the retina.
To perform Subtotal vitrectomy can be used invasive sutureless vitreoretinal technology caliber 25Ga or 23Ga. Minimizing operative trauma, delicate and well-controlled work vitreal tools, no need for suture fixation make this technology is safe and well tolerated. Destruction of the posterior hyaloid membrane improves the permeability of retinal introduced to drugs and facilitates the deployment of the blood.
The method is as follows.
After retrobulbar the Noah anesthesia and akinesia processing operating margins in the operating conditions perform a three port vitrectomy 25-gauge in the Subtotal volume with removal of the posterior hyaloid membrane. Next, after removing the "ports" - cannulas and restore integrity vitreal cavity by the slight hypotonia intravitreal under visual control through the flat part of the vitreous body in 3-4 mm from the limbus (depending on the anatomical length of the eyeball) with injection needle 30-gauge sequentially injected diluted solution of recombinant prourokinase 500 ME and 0.15 ml involving bevacizumab Then in the eye cavity is injected with 0.4-2.0 ml 100% gas perftoran
(C3F8or sulfurhexafluoride (SF6). Control the tightness of the scleral tunnels, the level of intraocular pressure, perform subconjunctival injection of dexamethasone and gentamicin succinate. Within two hours after surgery, patients observe bed rest on the back contact of the products with subretinal haemorrhage and subsequent positioning face down in 2-3 days, providing the most effective impact of the bubble gas hemorrhage in the macular region.
The indication for the use of the method is subretinal haemorrhage on the background of age-related macular degeneration with SNM when the duration of bleeding is not more than 4 weeks (optimal period not exceeding two weeks).
Example 1. Patient M., 56 years old, with diagnosis OU - high myopia, subretinal neovascular the RNA membrane, OD - and subretinal intraretinal hemorrhage, he began to notice the emergence of a vast spot in front of the right eye and a sharp deterioration of vision in the last 2 weeks. Visual acuity of the right eye was eccentric account of the fingers 30 cm without correction visual acuity of the left eye 0,02 sph-13.5 D=0.4. IOP on Maklakova OD - 18 mm Hg, OS - 16 mm Hg Objectively in the fundus of the right eye was determined massive subretinal haemorrhage, completely overlying the macular area, the upper and lower major vascular arcades. According to the OST revealed extensive hemorrhagic detachment of the pigment epithelium in excess of the scan area. The relative size of the hemorrhage was 8 disc diameters (DD). Absolute scotomas in the Central area corresponds to the area of hemorrhage. According to the In-scan height prominence in the vitreous body of 4.11 mm In the left eye was determined by a small detachment of the pigment epithelium with extrafoveal located subretinal neovascular membrane, peripheral chorioretinal dystrophy, limited by the laser coagulates. According to ERG OD - significant changes in all layers of the retina, including macular area, OS - moderate changes in all layers of the retina with the capture of the Central zone. On the right eye was performed, surgery is on the above-described method, the operation and the postoperative period was uneventful. The effect of shifting subretinal hemorrhage from the macular region was observed already at the second day after surgery. The visual acuity improved to 0.02 n/a, the value of IOP was 17 mm Hg, according to the In-scan was determined dislocation subretinal hematoma in the lower-inner quadrant, height prominence was 2,97 mm In the macular area, free from bleeding, was determined by extensive subretinal neovascular membrane, surrounded by a nimbus of hemorrhages. According to microperimetry in the area of original location of the hematoma remained absolute scotoma, indicators ERG has not changed. At the control examination after 1 month after surgery, the visual acuity OD amounted to 0.03 sph-12.0=0.2, IOP - 19 mm Hg, linear dimensions subretinal neovascular membrane according to optical tomography 2053µ, remained Corolla small hemorrhages around her, acoustically, there was complete seal membranes of eyes. According to microperimetry area absolute scotomas in the Central visual field was reduced to 10°. The presence of extensive SNM required additional intravitreal injection involving bevacizumab 2 months after the initial intervention showed positive visual acuity: OD 0.035 sph-12.0=0.3, sizes CNM socraties is to 1709µ, hemorrhagic activity was absent. When control inspections throughout the entire follow-up period (1 year) visual acuity remained stable, recurrent subretinal hemorrhages were noted, neovascular membrane was at the stage of fibrosis, complications such as retinal detachment was not observed.
Example 2. Patient, 67 years, the diagnosis OU - age-related macular degeneration, primary age-related cataract. OD - subretinal hemorrhage. Prescription sharp deterioration 3 weeks. Visual acuity of the right eye account of the fingers of a person, the visual acuity of the left eye of 0.3 sph+0.5D cyl+1.0 ax 22°=0.4. The magnitude of IOP OD - 16 mm Hg, OS - 18 mm Hg In the macular area of the right eye was determined subretinal haemorrhage dimensions of 5.5 (DD) with areas of subretinal seal. The length of hemorrhagic retinal pigment epithelium according to the OST was 6000µ. According to microperimetry in the Central zone was determined absolute scotoma corresponding to the area of subretinal hemorrhage. On the left eye in the Central region was visualized multiple friends with detachment of the pigment epithelium in length 2060µ. According to electroretinography there was a decrease in function of a cone apparatus in the Central zone, the reduction of macular ERG. On the right eye was performed surgical procedure in the above-described m codice, the operation and the postoperative period was uneventful. On the second day after the operation there was a partial offset hematoma with preservation in the Central zone foci subretinal proliferation. Visual acuity was OD - 0,05. Indicators ERG has not changed. When discharged on the fifth day after surgery was determined complete dislocation hematoma from a Central area of the retina. Visual acuity improved from 0.05 to 0.1. The magnitude of IOP OD - 18 mm Hg After month after surgery in the macular area was determined dense fibrovascular film without signs of activity, with clear contours, sizes subretinal membrane according to the OST was 3278µ, visual acuity was significantly limited subfoveal located SNM and not exceed 0.15 n/K. When control inspections throughout the entire follow-up period (1 year) visual acuity remained stable, recurrent subretinal hemorrhages were noted, neovascular membrane was at the stage of fibrosis, complications such as retinal detachment was not observed.
Thus, the proposed method allows researchers to simultaneously achieve anatomical evacuation of blood from the Central zone of the retina, the stabilization process choroidal neovascularization and minimize the risk of intra - and postoperative complications in early and late p is ridah.
The method of surgical treatment of subretinal hemorrhage on the basis of age-related macular degeneration with subretinal neovascular membrane, including intravitreal injections of tissue plasminogen activator and the expanding gas perftoran (C3F8or sulfurhexafluoride (SF6with the subsequent positioning of the patient's face, wherein the pre-to intra-vitreal injections perform Subtotal vitrectomy with removal of the posterior hyaloid membrane and the introduction of intravitreal bevacizumab or ranibizumab.
SUBSTANCE: group of inventions concerns ophthalmology and can be used for depression of level of serumal amyloid A protein (SAA) in tissues with glaucomatous changes, for diagnostics of glaucoma and determination of agents, potentially applicable for glaucoma treatment. The ways of SAA levels decrease provide contacting of glaucomatous tissues with agents which interact with a gene modulating SAA expression or inhibit interaction of the SAA protein with its receptor. Methods of diagnostics include obtaining of a biological material from the patient, analysis of the material and conclusion about glaucoma presence at detection of high level of bioactivity, mutation of genes or products of SAA genes. The method of determination agents, potentially applicable for glaucoma treatment includes modes of formation of the reactionary admixture containing cells, including the recombinant SAA protein or expression vectors, and an investigated bond; a stage of definition of effect of a signal transmission in the presence of a tested bond and conclusion formation about possibility of use of an agent for glaucoma treatment if there are changes of a signal transmission in the presence of a tested bond.
EFFECT: increase of efficiency of diagnostics and glaucoma treatment.
13 cl, 5 dwg, 1 tbl, 5 ex
SUBSTANCE: invention concerns medicine, namely ophthalmology, and involves use of suspended cultivated neuronal self-cells precipitated from olfactory region of nasal mucosa, or cultivated mesenchymal self-cells precipitated from bone marrow. Stem cells are introduced suprachoroidally in amount 500 thousand per 0.02 ml of physiologic saline or retrobulbary 1.5 million per 0.3 ml of physiologic saline. The introduction is repeated 20-30 days later.
EFFECT: method allows for prolonged and adequate improvement of capacity and reparative activity of retina with various pathologies.
2 cl, 6 dwg, 1 ex
SUBSTANCE: present invention refers to the aminopyridin compound of general formula (I) or its salt wherein X1, X2, X3, Z, Y1, Y2 are carbon or nitrogen atom, R, R1, R5, R6 are hydrogen atom, alkyl group, further see formula of the invention, and R7 is hydrogen or halogen atom, nitro or cyano group, -CpH2(p-1)(Ra1)(Ra2)-O-Ra3, -C(=O)-Rd1, 5-or 6-membered saturated heterocycle group, aromatic heterocycle group, -N(Rh1)(Rh2), further see formula of the invention. The invention refers also to the pharmaceutic composition thereof intended for treatment or prevention of allergic diseases, autoimmune diseases caused by malignant tumour, to the Syk inhibitor containing the compound of formula I and to the therapeutic and/or preventive agent.
EFFECT: compounds which not only possess high Syk inhibition activity but are selective Syk inhibitors are obtained and described.
24 cl, 24 ex, 2 tbl
SUBSTANCE: present group of inventions relates to medicine, more specifically to ophthalmology and treatment of pathological processes in the cornea. For this purpose pharmaceutical compositions are locally used, containing one active component in form of urea or urea derivative, and a second active component in form of a compound, chosen from a group consisting of citric acid, dibasic potassium phosphate, isopropyl alcohol, sorbite, propylene glycol, polyethyleneglycol, block-polymer polyatomic alcohol and antimetabolites, in sufficient quantities with pH between 4.0 and 8.0.
EFFECT: softening of the cornea during surgery-substitute refractive vision correction, as well as increased clarity of the cornea due to readjustment of collagen.
26 ex, 20 cl
SUBSTANCE: invention refers to medicine, namely to ophthalmology, and aims at therapy of corneoconjunctival xerosis. The anterior surface of eyeball is covered with a dried with silicon plasticised amniotic membrane comprising a disk sized 8 to 10 mm, thereafter fixed with a silicone-hydrogel soft contact lens. Aqueous solution of sodium hyaluronate 0.1% is instilled into conjunctival cavity 4-5 times within one hour. Then instillation is carried out 3-4 times a day. Five days later, the soft contact lens is removed from the eyeball surface.
EFFECT: method allows improving effectiveness of conservative therapy and reducing length of lacrysubstitutive therapy.
2 ex, 1 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions concerns medicine, namely to ophthalmology, and concerns use of combretastatin and its phosphatic promedicine for treatment or prevention of a pathological myopia.
EFFECT: improvement of visual acuity at the patient, suffering a pathological myopia, reduction of the exudative phenomena, induction regresses of proliferation of vessels, suppression of growth of a proliferating vascular tree.
40 cl, 5 dwg, 12 tbl, 10 ex
SUBSTANCE: application of the oxidised ATF form (o-ATF) as the antiangiogenic pharmacological agent, a therapeutic preparation for treatment of the tumours, including o-ATF with antitumoral substance and a therapeutic preparation for treatment of the atherosclerotic processes, containing o-ATF with antiatherosclerotic substances is offered. The agent is applicable for treatment of diseases, in whose beginning or advance the angiogenesis, such as diseases of eyes, atherosclerotic processes or tumours is involved.
EFFECT: maintenance of suppression of a proliferation of endothelial cells, or anti-angiogenic effect even in the presence of the endothelial factor of growth of vessels.
6 cl, 2 dwg, 2 ex
SUBSTANCE: invention relates to field of medicine - ophthalmology. Medication for prevention and treatment of ophthalmlogical diseases contains active substance, gel-former, sodium chloride, sorbitol, buffer, conservative, water and disodium edentate. As active substance ethylmethylhydroxypyridine succinate is used; as gel-former - polyacrylic acid, hydroxyethylcellulose, sodium-carboxymethylcellulose, hydroxypropylcelulose or healon; as buffer phosphate buffer is used, which includes sodium hydrophosphate - 0.2-2.0% and potassium dihydrophosphate 0.05-1.0%, or citrate buffer, which includes sodium hydrocytate - 0.5-2.5% and sodium hydroxide 0.05-1.5%; as conservative - cetrimide.
EFFECT: increase of efficiency of antioxidative and antihypoxic protection.
4 cl, 2 ex
SUBSTANCE: invention relates to ophthalmology and is intended for choroid melanoma treatment. Method lies in combination of two mechanisms of tumor destruction and two methods of treatment. First, local influence on tumor surface with laser radiation with wavelength 810 nm, exposition 60 seconds, with power density from 400 to 1700 mW, light spot diametre from 600 to 5000 mcm is performed. Influence is performed until even white colour appears on tumor surface. 1-14 days after thermotherapy at the peak of hematoophtalmological barrier damage system chemical therapy is performed three days running. Aranose, introduced intravenously calculating 600-1000 mg/m2 in 250 ml of 5% glucose solution, is used. In case of incomplete tumor regression sessions of chemical therapy are repeated thrice with 3 week interval. In case if complete tumor regression with formation of flat chorioretinal scar does not take place, course of treatment is repeated.
EFFECT: ensuring full tumor destruction to formation of flat chorioretinal scar, which leads to increase of choroid melanoma treatment efficiency and extends possibilities of organ-preserving treatment methods on the whole.
3 cl, 1 ex
SUBSTANCE: invention relates to medicine, namely to ophthalmology, and is intended for treatment of infectious inflammatory eye diseases. Into eye conjunctiva cavity 4-6 times a day during 5-7 days 0.1 ml of gel which has the following composition: water-soluble cellulose derivative with concentration 20 mg/l in amount 7 ml, sodium hypochlorite water solution with concentration 250-300 mg/l in amount 3 ml is applied.
EFFECT: creating maximal concentration of medicinal substance on local area.
SUBSTANCE: invention concerns biotechnology. The methods of angiogenesis depression or inhibition at an individual with the pathological condition bound to an angiogenesis, providing administration of antagonist EGFL7 to an individual, capable interfering migration of endothelial cells induced by EGFL7, thereby reducing or inhibiting an angiogenesis at an individual is described. The invention can be used for regulation of the processes involved in an angiogenesis.
EFFECT: development of an effective way of depression or inhibition of an angiogenesis at an individual with the pathological condition bound to angiogenesis.
13 cl, 38 dwg, 4 ex
SUBSTANCE: invention refers to medicine and biotechnology area and concerns antibody polypeptides ensuring monovalent binding of CD40L. Substance of the invention involves antibody polypeptides ensuring monovalent binding of CD40L and can inhibit activity of CD40L while allowing avoiding potential undesirable results of application of antibodies able for bivalent and multivalent binding of CD40L. In one perspective, polypeptide of monovalent anti-Cd40L antibody consists of, or contains single variable immunoglobulin domain which specifically binds and inhibits activity of CD40L, preferentially to a wide extent not stimulating activity of CD40 and/or CD40L. In the other perspective, polypeptide of monovalent anti-Cd40L antibody represents human antibody polypeptide. The present invention also involves methods of CD40/CD40L interaction inhibition in a human organism and therapies of diseases or disorders involving CD40/CD40L interactions, including introduction to a patient of polypeptide of monovalent anti-CD40L antibody.
EFFECT: advantage of the invention consists in higher specificity.
73 cl, 9 ex, 13 dwg
FIELD: veterinary medicine.
SUBSTANCE: invention relates to the field of veterinary medicine. Method provides for ingesting 70% alcoholic tincture of common pine buds, purple echinacea herbs and inflorescences and elfwort rootstocks and roots, taken in ratio of 2:1:1. Alcoholic tincture is obtained at one - to- five ratio of raw material to extractor and then held at a temperature of 18-20°C for 7 days. Alcoholic tincture is used in form of 7-8% aqueous solution. For preventive measures it is taken in dose of 1.0-1.5 ml to one kilogramme of animal live weight with interval of 24 hours during 7-10 days. For treatment measures it is taken in dose of 2.0-3.0 ml to one kilogramme of animal live weight with interval of 12 hours to the moment of clinical recovery. Herewith hypodermic injection of convalescence serum, containing specific antibodies to rota-coronaviruses in titers 1:128 and 1:64 correspondingly, is given in dose of 10.0 ml with interval of 48-72 hours during 9 days.
EFFECT: method lets form common nonspecific adaptative reaction of increased activation which is characterised by enhanced resistance and different types of metabolism balance, secondary to passive immunisation against rota-coronaviruses.
4 tbl, 3 ex
SUBSTANCE: invention concerns immunology area. Versions of the artificial fused protein consisting of an antibody (or its fragment) and cytokine, fused through a link peptide are offered. The antibody or its fragment is chosen from an antibody 225, 425, KS 1/4, 14.18, anti-CDx-antibody where x has the whole value 1-25. Each of versions of the fused protein has lowered quantity T-epitopes, at least, in the component of the fused protein presented by an antibody, and as consequence, possesses the lowered adjuvanticity, in comparison with an initial molecule. Identification of T-lymphocyte epitopes is performed by the automated calculation of sizes for the binding centres of class II MHC molecules with the subsequent experimental test of the obtained versions of protein for presence of the lowered adjuvanticity. The automated way of T-epitopes calculation is based on use of the Bjom's function modified in such manner that contribution of Van-der-vaals repulsion and lipophilic interaction in pairs between all lipophilic atoms of the chosen segments of the fused protein and a binding groove of a MHC P molecule is taken into account. Also a way of protein construction on the basis of the modified function Bjom's function with the subsequent experimental test of the received versions for presence of the lowered adjuvanticity is revealed, and also application of the fused protein for preparation of a pharmaceutical composition for tumour treatment is in addition considered.
EFFECT: invention use allows obtaining the fused proteins with the lowered adjuvanticity and, basically, keeping identical biological activity in comparison with a parent molecule; it can be used in treatment of tumours.
4 cl, 6 dwg, 22 tbl, 19 ex
SUBSTANCE: invention concerns veterinary science area. The way includes injection of a nonspecific immunoglobulin. In addition 70% spirituous tincture of the crushed vegetative admixture of pine buds, grass and inflorescences of coneflower, rhizomes and roots of horseheal, taken in the ratio 1:1:1. The spirituous tincture is obtained at a parity of raw materials and an extractor 1:5 and maintained at temperature 18-20°C within 7 days. Animals obtain the tincture in the form of a 7-8% aqueous solution in a dose of 1.0-1.5 ml/kg of live weight within 15 days with a 24 hours interval. The way allows stimulating humoral and cellular immunity effectively.
EFFECT: possibility to stimulate humoral and cellular immunity effectively.
4 tbl, 3 ex
SUBSTANCE: invention relates to medicine, more specifically to endocrinology, cardiology and rheumatology and correction of metabolic syndrome in patients with deforming ostheoarthrosis. For this purpose in addition to traditional therapy with non-steroidal anti-inflammatory drugs and antihypertensive therapy agents, arthrofoon is sublingually administered 1 tablet four times a day, together with siofor in a dose of 500 mg 2 times a day for 12 months.
EFFECT: effective correction of metabolic and articular disorders due to synergetic effect of arthrofoon and siofor, taken in the given doses and regimes.
FIELD: chemistry, biochemistry.
SUBSTANCE: claimed invention relates to immunology and biotechnology. Claimed are versions of neutralising antibodies or their functional analogues against human NOGO-A, each of which is characterised by set of specific CDR. Described is pharmaceutical composition for human NOGO-A neutralisation. Described are versions of application of antibodies or their functional analogues in production of medication for treatment and/or prevention of neurological diseases/ disorders. Described is method of axon growth stimulation using antibodies of invention.
EFFECT: ensuring neutralising antibodies with high affinity to human NOGO-A, with KD of 10-9 M, which can be further applied in medicine for activation of neurite growth.
17 cl, 45 dwg, 14 tbl, 18 ex
SUBSTANCE: described is a composition for treating cancer, containing the main type of HER2 antibody, which is linked with the II domain in HER2, and its versions on amino acid sequence, with a leader elongation at the amino-end.
EFFECT: invention increases assortment of drugs, used for treating cancer.
6 cl, 31 dwg, 7 tbl, 1 ex
SUBSTANCE: proposed is a chimeric or humanised monoclonal antibody against hepatocyte growth factor, produced from L2G7 antibody. Invented is a mouse antibody L2G7, produced by hybridoma ATCC PTA-5162, and the said hydbridoma. Described is a cell line, producing a chimeric or humanised monoclonal antibody against hepatocyte growth factor. Proposed is a pharmaceutical composition and a method of treating tumours based on the said antibody.
EFFECT: use of the invention provides for a neutralising antibody against hepatocyte growth factor, which can be used in treating human cancer.
7 cl, 12 dwg, 1 tbl, 3 ex
SUBSTANCE: group of inventions concerns medicine, namely, to oncology and can be used for treatment of the cancer expressing intergrin α5β1. The ways under the invention include introduction of the liquid pharmaceutical composition containing 0.1-15 mg/ml of an antibody against α5β1 to the patient.
EFFECT: possibility to suppress proliferation and to prevent diffusion of a tumour at the expense of direct lysis of cancer cells at fixation by an intergrin α5β1 antibody on their surface.
22 cl, 2 dwg, 6 tbl, 9 ex
SUBSTANCE: polypeptides include single-domain antibody against vWF, A1 domain of vWF, A1 domain of activated vWF, A3 domain of vWF, gp1b and/or collagen. Invention claims methods of obtaining indicated polypeptides, methods of coating devices applied in medical practice (e.g. in X-ray structural analysis, endoprosthetics) with indicated polypeptides.
EFFECT: obtainment of polypeptides for treatment of diseases requiring modulation of thrombocyte-mediated aggregation.
40 cl, 69 ex, 30 dwg, 32 tbl